Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS

Next Previous
Trial Profile

A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Debamestrocel (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Brainstorm Cell Therapeutics

Most Recent Events

  • 30 Mar 2023 According to a Brainstorm Cell Therapeutics media release, data from this study were presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
  • 01 Jan 2023 Preliminary results (n=18) assessing the safety and efficacy of three intrathecal cell treatments in progressive multiple sclerosis patients, published in the Multiple Sclerosis Journal.
  • 20 Oct 2022 According to a Brainstorm Cell Therapeutics media release, data from this study will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top